BUFFALO, N.Y., June 18, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced the launch of an updated website emphasizing the Company's broad oncology drug pipeline. The website address is: http://www.cbiolabs.com and the site incorporates interactive messaging and enhanced navigation.
Yakov Kogan, Ph.D., MBA, Chief Executive Officer, stated, "Since the launch of our prior website, the breadth of our drug candidate pipeline has expanded and we have matured into a clinical-stage oncology company. We have multiple clinical trials in oncology currently underway, with more planned. Our new website is designed to draw the visitor's focus to our targeted oncology and orphan indications, as well as our biodefense application. The new website also includes expanded technical information for potential partners and for others interested in our scientific fundamentals."
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging deep mechanistic understanding of the cell death process, apoptosis, to develop a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The Company's lead compound is being developed as both a radiation countermeasure and a cancer treatment. The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs, Inc., and strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website athttp://www.cbiolabs.com.
The Cleveland BioLabs, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11668
| Contact: |
| Rachel Levine, Director Investor Relations & Communications |
| Cleveland BioLabs, Inc. |
| E: rlevine@cbiolabs.com |